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Abstract
Limited data are currently available on the outcome of patients with acute myeloid 
leukemia (AML) undergoing allogeneic stem cell transplantation (allo-SCT) with 
a reduced performance status. We herein present the results of a registry study on 
2,936 AML patients undergoing allo-SCT in first remission (CR1) with a Karnofsky 
Performance Status (KPS) score less than or equal to 80%. Two-year leukemia-free 
survival (LFS), overall survival (OS) and graft-versus-host disease (GVHD)-free, 
and relapse-free survival (GRFS) rates were 54%, 59%, and 41%, respectively. In 
multivariable analysis, patients with a KPS score = 80% had lower non-relapse mor-
tality (NRM) and superior OS in comparison to patients with a KPS score  <80% 
(p < 0.001). In the subgroup of patients with a KPS score =80%, a reduced-inten-
sity conditioning (RIC) regimen was associated with an increased risk of relapse 
(p = 0.002) and lower GRFS (p < 0.001) compared to myeloablative conditioning 
(MAC). Differently, in patients with a KPS score <80%, a RIC regimen resulted in 
lower NRM (p < 0.001), whereas relapse incidence did not differ, thus leading to 
an improved GRFS (p = 0.008) as compared to MAC. A transplant from a matched 
sibling donor (MSD) was associated with a reduced incidence of grade III-IV acute 
GVHD (p < 0.01) and NRM (p < 0.01) in comparison to other donor types. In con-
clusion, allo-SCT appears feasible in AML patients with a jeopardized KPS score. 
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1 |  BACKGROUND
Allogeneic stem cell transplant (allo-SCT) is a mainstay of 
post-remission treatment for acute myeloid leukemia (AML). 
Nevertheless, this procedure is saddled with a significant 
risk of mortality, especially in patients undergoing trans-
plant with an impaired physical condition. Different models 
have been designed with the aim to identify the patients that 
are able to tolerate a transplant, and to adjust the procedure 
according to patient fitness. Commonly used scales are the 
Charlson Comorbidity Index (CCI),1 Hematopoietic Cell 
Transplantation-specific Comorbidity Index (HCT-CI),2 and 
Karnofsky Performance Status (KPS) score,3 each catch-
ing different aspects of patient condition before transplant. 
KPS represents a robust measure of global health status, and 
a reliable predictor of non-relapse mortality and survival 
after transplant for different hematological malignancies.4–9 
Furthermore, it has the advantage of allowing a dynamic as-
sessment which is extremely easy to perform. Historical data 
show a dismal outcome for patients undergoing transplant 
with a jeopardized performance score.10–14 However, with the 
availability of low-intensity induction regimens for AML,15–
17 the recent design of different reduced-intensity condition-
ing (RIC) protocols,18–20 the expansion of donor sources,21 
and the significant improvement in supportive care,22,23 an 
increasing number of AML patients with a jeopardized per-
formance score are considered for an allo-SCT. Nevertheless, 
limited evidence is available about transplant outcomes in 
this delicate setting. We herein present the results of a retro-
spective analysis conducted on a large, homogeneous cohort 
of AML patients with a KPS score less than or equal to 80%, 
undergoing allogeneic transplant in first remission (CR1).
2 |  PATIENTS AND METHODS
We included in the analysis patients diagnosed with AML 
older than 18 years, who underwent an allo-SCT in first com-
plete remission between 2000 and 2018, with a KPS score 
at the time of transplant ranging from 50% to 80%. Patients 
received a transplant from a matched sibling donor (MSD), 
matched unrelated donor (MUD), mismatched unrelated 
donor at one HLA locus (MMUD), cord blood (CB), or hap-
loidentical (haplo) donor. All transplants from haplo donors 
were performed using an unmanipulated, T-cell replete graft. 
Conditioning intensity (myeloablative, MAC; reduced inten-
sity, RIC) was defined according to EBMT standards.24 A 
complete list of EBMT centers contributing data to this study 
is presented in Table S4, Supplementary file.
Non-relapse mortality (NRM) was defined as death with-
out prior recurrence of the disease. Relapse was defined 
according to standard criteria for AML. Leukemia-free 
survival (LFS) was defined as survival in the absence of 
relapse. Overall survival (OS) was estimated from the day 
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of transplant until death or last follow-up. Graft-versus-host 
disease (GVHD)-free, relapse-free survival (GRFS) was de-
fined by the first of the following events: acute grade III-IV 
GVHD, severe chronic GVHD, relapse, or death. LFS, OS, 
and GRFS were calculated using the Kaplan–Meier method; 
NRM, relapse, and GVHD were calculated by cumulative in-
cidence analysis considering competing risks. For univariate 
comparisons, the log-rank test was employed for LFS, OS, 
and GRFS, whereas the Gray's test was used for GVHD, re-
lapse incidence, and NRM. The Cox model was employed 
for multivariate analyses. In order to investigate prognostic 
factors in this population, all factors associated with one 
outcome in univariate analysis with a p value less than 0.05 
or variables deemed conceptually important were included 
in the Cox model. We investigated more specifically con-
ditioning intensity in the population of patients receiving 
transplant from MSD or MUD. As we found a qualitative 
interaction between conditioning intensity and KPS, further 
analyses were stratified on KPS value equal or less than 80. 
All p-values were two-sided, and p < 0.05 was considered 
statistically significant. Statistical analyses were performed 
with the SPSS 24 (SPSS Inc./IBM, Armonk, NY, USA) and 
R 3.6.2 (R Development Core Team, Vienna, Austria) soft-
ware packages.
3 |  RESULTS
3.1 | Patient, disease, and transplant 
characteristics
A total of 2,963 patients were included in the study. The 
median age at transplant was 55 years (range 18-77 years). 
Patients with secondary AML were older as compared to 
patients with de novo AML. The KPS score was =80% in 
85% of the patients and <80% in 15% of the patients. Donor 
type was MSD, MUD, MMUD, haplo, or CB in 47%, 35%, 
8%, 6%, and 4% of the patients, respectively. A myeloab-
lative (MAC) or reduced-intensity (RIC) conditioning was 
administered in 42% and 58% of the patients, respectively. 
Most common MAC regimens included busulfan and cyclo-
phosphamide (BuCy, 28%), busulfan and fludarabine (BuFlu 
with busulfan dose equal to or greater than 9.6 mg/kg, 27%), 
or cyclophosphamide and total-body irradiation (CyTBI, 
23%); most common RIC regimes included BuFlu (busul-
fan dose equal to or lower than 6.4 mg/kg, 47%), fludarabine 
and melphalan (FluMel, 11%), and fludarabine-TBI (16%). 
Conditioning regimens details are presented in the supple-
mentary file, Table S1.
Graft-versus-host disease (GVHD) prophylaxis regi-
mens included cyclosporine combined with methotrexate 
(CSA+MTX) or with mycophenolate mofetil (CSA+MMF) 
or CSA alone in 37%, 27%, and 15% of the patients, 
respectively. Anti-thymocyte globulin (ATG) was adminis-
tered to 55% of the patients. Patient characteristics are de-
tailed in Table 1.
3.2 | Engraftment and graft-versus-
host disease
Successful engraftment was achieved by 98% of the patients. 
The median day of neutrophil recovery (defined as achieving 
an absolute neutrophil count of 500/L) was 18 (range 2-72). 
Cumulative incidence of grade II-IV and III-IV aGVHD was 
26% and 8%, respectively. Cumulative incidence of cGVHD 
at 2 years was 38%; severe cGVHD was observed in 18% of 
the patients. Incidence of grade II – IV aGVHD was lower 
after MSD transplant as compared to other donor types 
(MUD: p  =  0.001; MMUD: p  <  0.001; haplo: p  <  0.001; 
CB: p  <  0.001; MSD as reference, Table 2). Similarly, a 
transplant from a female donor was independently associated 
with an increased rate of grade III-IV aGVHD (p = 0.03). 
Furthermore, donor type was independently associated with 
the incidence of severe cGVHD: compared to the reference 
group MSD, CB transplant resulted in inferior incidence 
(p = 0.009), whereas 10/10 UD resulted in higher incidence 
(p = 0.007) of severe cGVHD, respectively. A non-signif-
icant trend toward a reduced incidence of severe cGVHD 
(p  =  0.06) was noted for haploidentical transplantation as 
compared to other donor types. Notably, ATG administra-
tion resulted in a lower incidence of grade III-IV aGVHD 
(p < 0.001) and severe cGVHD (p < 0.001).
3.3 | Non-relapse mortality, 
relapse, and survival
Two-year NRM and relapse rates were 19% and 27%, respec-
tively. Common causes of death included leukemia relapse 
(44%), infection (21%), and GVHD (19%).
Leukemia-free survival (LFS), OS and GRFS rates were 
54%, 59%, and 41%, respectively. In multivariable analysis, 
MSD (reference group) resulted in a significantly reduced risk 
of NRM as compared to other donor types (MUD: p = 0.006; 
MMUD: p < 0.001; haplo: p = 0.004; CB: p = 0.001, Table 
2). MUD transplant resulted in inferior GRFS (p  =  0.03), 
whereas MMUD was associated with inferior LFS, OS, and 
GRFS (p < 0.001) as compared to MSD (Figure 1, Table 2). 
There was no significant difference in survival outcomes fol-
lowing haplo or CB compared to MSD transplant.
We evaluated the influence of KPS score on NRM, com-
paring patients with KPS =80% with patients with KPS <80%. 
Patients with a KPS <80% showed higher non-relapse mor-
tality and inferior survival when compared to patients with a 
KPS =80% (NRM: p < 0.01; OS: p < 0.001). Other factors 
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T A B L E  1  Patient characteristics
KPS score =80% KPS score <80% p value
Total number included in analysis 2522 441
Follow up (months), median (IQR) 35.4 (12.3 - 89.7) 25.3 (12.3 - 61.9) 0.001
Age of patient at HSCT (years), Median (range) 
(IQR)
55 (18 - 76) (44 – 62) 56 (19-77) (48-62) 0.05
Year of transplant, median (range) 2014 (2000-2018) 2015 (2000-2018) 0.19
Diagnosis, n (%)
De novo AML 2146 (85%) 348 (79%) 0.001
Secondary AML 376 (15%) 93 (21%)
Gender of patient, n (%)
Male 1311 (52%) 211 (48%) 0.1
Female 1208 (48%) 230 (52%)
HCT-CI at transplant, n (%)
HCT-CI =0 667 (52%) 108 (41%) 0.01
HCT-CI 1-2 276 (21%) 69 (26%)
HCT-CI >2 347 (27%) 84 (32%)
Missing 1232 180
Interval from diagnosis to SCT (months), 
median (range) (IQR)
4.7 (0.7-17.8) (3.8-6.1) 4.9 (0.8-17.9) (3.8-6.3) 0.22
Interval from diagnosis to CR1 (days), median 
(range) (IQR)
49 (1-476) (36-73) 52 (20-401) (37-78) 0.2
Interval from CR1 to SCT (days), median 
(range) (IQR)
91 (2-391) (59-126) 90 (10-341) (57-140) 0.55
Cytogenetics, n (%)
Favorable 155 (6%) 17 (4%) 0.12
Intermediate 1712 (68%) 299 (68%)
Adverse 655 (26%) 125 (28%)
WBC at diagnosis (x 109/L), median (range) 
(IQR)
7.8 (0.2-665) (2.4-40) 7.0 (0.3-790) (2.5-37.9) 0.4
Donor Type, n (%)
MSD 1186 (47%) 221 (50%) 0.18
UD 10/10 889 (35%) 139 (32%)
UD 9/10 206 (8%) 34 (8%)
TR Haplo 161 (6%) 25 (6%)
CBT 80 (3%) 22 (5%)
Donor/recipient sex mismatch, n (%)
F->M 2078 (83%) 366 (83%) 0.86
No F->M 436 (17%) 75 (17%)
Stem cell source, n (%)
BM 367 (15%) 40 (9%) 0.002
PBSCs 2075 (82%) 379 (86%)
CB 80 (3%) 22 (5%)
Conditioning intensity, n (%)
MAC 1108 (44%) 144 (33%) <0.001
RIC 1414 (56%) 297 (67%)
(Continues)
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associated with poor survival in multivariable analysis were 
older patient age, male gender, poor-risk cytogenetics, and 
secondary AML (Table 2). In particular, patients with sec-
ondary AML had significantly higher relapse and lower 
OS as compared to patients with de novo AML (p = 0.012, 
p < 0.0001, respectively). In this subgroup, KPS score <80% 
remained associated with higher NRM and inferior OS as 
compared to KPS =80% (p = 0.003, p = 0.001, respectively).
When comparing MAC and RIC conditioning regimens in 
patients receiving a MSD or MUD transplant, we found a sig-
nificant interaction between conditioning intensity and KPS 
score. Consequently, the two groups of patients according to 
KPS score (= 80% or <80%) were analyzed separately (Table 
S2, supplementary file). In the cohort of patients with a KPS 
score =80%, a RIC regimen was associated with higher re-
lapse (p = 0.002), and lower GRFS (p < 0.001) in comparison 
to those seen with MAC (Figure 2), whereas NRM was simi-
lar (p = 0.2). Differently, in patients with a KPS score <80%, 
a RIC regimen resulted in lower NRM (p  <  0.001), better 
LFS (p = 0.003), OS (p < 0.001), and GRFS (p = 0.008) in 
comparison to MAC conditioning, whereas incidence of re-
lapse did not differ (p = 0.9; Table 2, Figure 3).
In addition, MUD transplant was associated with higher 
NRM (p = 0.002) and a trend for worse GRFS (p = 0.05) in 
comparison to MSD in patients with a KPS score =80%; no 
statistically significant difference was observed in the sub-
group of patients with KPS <80%. In order to analyze the rel-
ative impact of KPS score and HCT-CI on patients outcomes, 
we performed a subgroup analysis in patients with available 
data about HCT-CI score (n = 1551). When HCT-CI score 
was included in multivariable analysis, KPS  <80% and 
HCT-CI >2 resulted independently associated with higher 
NRM and inferior survival. (Table S3, supplementary file).
4 |  DISCUSSION
With the development of targeted therapies and low-intensity 
protocols, many unfit patients diagnosed with AML are cur-
rently offered induction therapy with curative intent and if a 
remission is obtained, they are considered for an allo-SCT. 
This study aimed to analyze the outcome of a homogeneous 
population of frail AML patients undergoing allo-SCT in 
CR1. In our series of patients with a performance status 
≤80% we observed encouraging outcomes, with a long-term 
survival approaching 60%.
Assessment of patient capability to tolerate the transplant 
procedure is a major turning point along the AML treatment 
path. The KPS scale is widely used by clinicians as it rep-
resents a robust surrogate of patient global health status, and 
has been shown to be strongly associated with NRM and 
survival after transplant.3–6 Interestingly, in a recent study 
in which the authors aimed to develop a “machine-learning” 
based prognostic model for patients with acute leukemia 
undergoing transplant,25 the algorithm included KPS along 
with the main parameters associated with patient survival. 
Furthermore, in a recently published analysis by Carrè et al.25 
KPS emerged as most reliable predictor of NRM when com-
pared to other parameters such as age and HCT-CI. In our 
series, a threshold of KPS score set at 80% strongly dis-
criminated patient outcome. In fact, in patients with a KPS 
score =80%, the NRM rate was remarkably low, resulting in 
a long-term survival of above 60%, thus being comparable to 
the figures expected for fit patients undergoing allo-SCT.26 
This finding is in accordance with previous literature, as 
these patients have a slightly impaired performance status 
and, if translated to ECOG score, would be included in grade 
1.27 On the contrary, patients with a KPS score <80% showed 
high NRM and poor survival. Interestingly, in the subgroup 
of patients with a KPS =80%, a RIC regimen was associated 
with an increased incidence of relapse as compared to MAC, 
whereas NRM did not differ, thus translating into superior 
survival for MAC as compared to RIC conditioning. In con-
trast, in the subgroup of patients with a KPS <80%, a RIC 
regimen resulted in significantly reduced NRM and superior 
survival in comparison to MAC, in agreement with previous 
evidence.6,8
The choice of the conditioning intensity represents a 
major conundrum when approaching a patient with an im-
paired performance status. The recent development of 
reduced-intensity regimens has allowed a significant pro-
portion of unfit patients to undergo allo-SCT; nevertheless, 
an increased rate of relapse has been reported following RIC 
as compared to standard myeloablative regimens, especially 
KPS score =80% KPS score <80% p value
ATG used, n (%)
No 1145 (45%) 176 (40%) 0.032
Yes 1377 (55%) 265 (60%)
Some percentages do not add up to 100% because of rounding.
Abbreviations: AML, acute myeloid leukemia; ATG, anti-thymocyte globulin; BM, bone marrow; CB; cord blood; GVHD, graft-versus-host disease; KPS, Karnofsky 
performance status; LFS, leukemia-free survival; MAC, myeloablative conditioning; MSD, matched sibling donor; NRM, non-relapse mortality; OS, overall survival; 
PBSCs, peripheral blood stem cells; RI, relapse incidence; RIC, reduced-intensity conditioning; UD, unrelated donor; WBC, white blood cells.
T A B L E  2  (Continued)
28 |   SARACENI Et Al.
T A B L E  2  Multivariate analysis of transplant outcomes
Outcome HR (95% CI) p
RI Secondary AML vs de novo AML 1.3 (1.02-1.5) 0.03
Good risk (reference) 1
Intermediate risk 1.2 (0.8-1.8) 0.4
Poor risk 2.2 (1.45-3.31) <0.001
MSD (reference) 1
UD 10/10 0.8 (0.698-1.02) 0.09
UD 9/10 1.1 (0.854-1.52) 0.4
Haplo 0.9 (0.602-1.25) 0.4
CB 0.7 (0.436-1.14) 0.2
NRM Age (per 10 years) 1.3 (1.17-1.41) <0.001
Secondary AML vs de novo AML 1.4 (1.13-1.77) 0.002
KPS =80% vs <80% 0.6 (0.479-0.752) <0.001
MSD (reference)
UD 10/10 1.4 (1.1-1.79) 0.006
UD 9/10 2.4 (1.75-3.28) <0.001
Haplo 1.8 (1.2-2.57) 0.004
CB 2.04 (1.32-3.16) 0.001
Female vs male patient 0.8 (0.647-0.937) 0.008
Patient CMV positive serology 1.3 (1.01-1.55) 0.04
LFS Age (per 10 years) 1.1 (1.03-1.16) 0.002
Secondary AML vs de novo AML 1.3 (1.14-1.53) <0.001
Good risk (reference)
Intermediate risk 1.2 (0.857-1.56) 0.3
Poor risk 1.8 (1.31-2.42) <0.001
KPS =80% vs <80% 0.7 (0.636-0.867) <0.001
MSD (reference)
UD 10/10 1.03 (0.888-1.2) 0.7
UD 9/10 1.6 (1.26-1.92) <0.001
Haplo 1.2 (0.909-1.53) 0.2
CB 1. (0.831-1.58) 0.4
OS Age (per 10 years) 1.2 (1.1-1.24) <0.001
Secondary AML vs de novo AML 1.3 (1.12-1.54) <0.001
Good risk (reference)
Intermediate risk 1.1 (0.815-1.57) 0.5
Poor risk 1.7 (1.21-2.36) 0.002
KPS =80% vs <80% 0.7 (0.564-0.779) <0.001
MSD (reference)
UD 10/10 1.1 (0.92-1.27) 0.3
UD 9/10 1.7 (1.34-2.1) <0.001
Haplo 1.2 (0.891-1.58) 0.2
CB 1.2 (0.848-1.68) 0.3
Female vs male patient 0.9 (0.752-0.973) 0.02
Patient CMV positive serology 1.2 (0.997-1.34) 0.06
GRFS Secondary AML vs de novo AML 1.2 (1.05-1.39) 0.007
(Continues)
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in patients undergoing transplant with persistence of resid-
ual disease.28,29 Recent evidence30 consolidated the concept 
that a MAC regimen should not be withheld if the patient 
is deemed to be capable of tolerating it, and reduced inten-
sity regimens should be reserved for unfit patients. In his-
torical studies, a KPS score ≤80% has been reported to be 
Outcome HR (95% CI) p
Good risk (reference)
Intermediate risk 1.3 (0.986-1.67) 0.06
Poor risk 1.8 (1.36-2.36) <0.001
KPS =80% vs <80% 0.8 (0.712-0.947) 0.006
MSD (reference)
UD 10/10 1.2 (1.01-1.32) 0.03
UD 9/10 1.5 (1.26-1.86) <0.001
Female vs male patient 0.85 (0.762-0.94) 0.002
Female vs male donor 1.2 (1.04-1.29) 0.006
ATG used 0.8 (0.733-0.926) 0.001
aGVHD III-IV Good risk (reference)
Intermediate risk 2.5 (1.11-5.73) 0.03
Poor risk 2.3 (0.988-5.35) 0.05
MSD (reference)
UD 10/10 1.8 (1.28-2.63) 0.001
UD 9/10 3 (1.85-4.77) <0.001
Haplo 2.6 (1.58-4.32) <0.001
CB 3.7 (2.17-6.36) <0.001
Female vs male donor 1.4 (1.04-1.78) 0.03
ATG used 0.6 (0.441-0.802) <0.001
Patient CMV positive serology 0.7 (0.541-0.957) 0.02
cGVHD KPS =80% vs <80% 0.8 (0.667-0.988) 0.04
MSD (reference)
UD 10/10 1.2 (1.03-1.46) 0.02
UD 9/10 1.4 (1.02-1.79) 0.04
Haplo 0.7 (0.523-1.06) 0.09
CB 0.5 (0.329-0.818) 0.004
Female vs male patient 0.8 (0.741-0.973) 0.02
Female vs male donor 1.3 (1.15-1.52) <0.001
ATG used 0.6 (0.552-0.75) <0.001
Severe cGVHD MSD (reference)
UD 10/10 1.4 (1.1-1.83) 0.007
UD 9/10 1.2 (0.755-1.83) 0.5
Haplo 0.6 (0.331-1.02) 0.06
CB 0.3 (0.148-0.763) 0.009
Female vs male patient 0.7 (0.6-0.895) 0.002
Female vs male donor 1.6 (1.28-1.92) <0.001
ATG used 0.5 (0.427-0.672) <0.001
Note:: Only variables with p values <0.1 were included.
Abbreviations: ATG, anti-thymocyte globulin; CB, cord blood transplant; CMV, Cytomegalovirus; GRFS, graft-versus-host disease-free, relapse-free survival; GVHD, 
graft-versus-host disease; Haplo, haploidentical transplant; KPS, Karnofsky performance status; LFS, leukemia-free survival; MSD, matched sibling donor; NRM, 
non-relapse mortality; OS, overall survival; RI, relapse incidence; UD, unrelated donor.
T A B L E  2  (Continued)
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F I G U R E  2  Graft-versus-host disease-free, relapse-free survival in patients with KPS score =80% receiving MAC or RIC regimen
F I G U R E  1  Overall survival in patients with KPS score less than or equal to 80% according to donor type
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associated with decreased survival following allo-SCT,5,30,31 
thus discouraging clinicians to offer this potentially curative 
treatment to these patients. Of note, most previous studies 
included patients with mixed hematological malignancies 
and with active disease at the time of transplant. In fact, in 
order to limit confounders, we selected only AML patients 
undergoing allo-SCT in CR1. Furthermore, conditioning reg-
imens, donor sources, and supportive therapy have signifi-
cantly developed recently, leading to a profound evolution in 
transplant practice.32 Indeed, a significant proportion of the 
patients included in our study received modern myeloablative 
regimens as fludarabine combined with an alkylator at mye-
loablative dosage, commonly referred to as “reduced toxicity 
regimens”. Such protocols are believed to be associated with 
similar anti-leukemic effect but better tolerability as com-
pared to standard protocols as busulfan and cyclophospha-
mide or cyclophosphamide and total body irradiation,19 and 
should be regarded as protocols with intermediate intensity, 
sharing both MAC and RIC features, as shown by a recent 
study.33
Globally, the findings of the present analysis emphasize 
the strong predictive power of KPS score in AML patients 
undergoing allo-SCT; furthermore, they shed new light on its 
impact on clinical practice. First, a reduced performance sta-
tus should not be considered per-se a major obstacle in per-
forming a transplant in a patient with AML in CR1. Moreover, 
these data suggest to carefully distinguish between patients 
with a slightly reduced KPS score (i.e., =80%) and those with 
a markedly impaired performance status (i.e., <80%), when 
planning a transplant and selecting the conditioning regimen. 
In fact, a MAC regimen should not be withheld in the former 
patients, whereas a RIC protocol is associated with superior 
outcome in the latter category.
Interestingly, when HCT-CI score was included in multivari-
able analysis, KPS <80% and HCT-CI >2 resulted independently 
associated with higher NRM and inferior survival. This finding 
is consistent with previous evidence.4 In fact, HCT-CI and KPS 
capture different aspects of patient health status, and might be 
employed as complementary measures of patient fitness before 
transplant. Unfortunately, the amount of missing data did not 
allow to draw any definite conclusion about the influence of 
HCT-CI score on outcome in patients with KPS <80%.
When we analyzed different donor types, a transplant 
from a MSD was associated with better outcome, resulting in 
reduced incidence of aGVHD and lower NRM rates in com-
parison to other donor sources. In particular, an unrelated 
donor resulted in higher risk of GVHD, whereas MMUD 
transplant predicted significantly inferior survival. Notably, 
in our study a significant proportion of patients (288, 10% 
of the study population) received transplantation from CB 
or a haplo donor. This represents novel data, as the main 
prognostic models currently available derive from studies 
excluding patients receiving transplants from alternative do-
nors.34,35 Interestingly, we observed a promising outcome 
F I G U R E  3  Graft-versus-host disease-free, relapse-free survival in patients with KPS score <80% receiving MAC or RIC regimen
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in this subgroup of patients receiving a CB or haplo trans-
plant. Survival was similar to matched unrelated donor and 
superior to mismatched unrelated donor; furthermore, lower 
rates of severe cGVHD were observed, consistent with recent 
publications.36
This study carries some limitations, mainly related to its 
retrospective design and non-randomized patient allocation 
to different groups, which could have influenced the results. 
Nevertheless, a prospective, randomized study enrolling 
frail AML patients undergoing allo-SCT is not available 
and hardly likely to be conducted in the near future; thus, 
the findings of the present analysis could be of guidance for 
clinical practice.
In conclusion, allogeneic transplant appears feasible in 
AML patients with a reduced performance score. Outcome 
varied significantly depending on conditioning intensity, 
which should be adjusted according to the severity of 
KPS impairment. In fact, in patients undergoing transplant 
with a slightly reduced KPS score (=80%), a MAC regi-
men provided inferior relapse and better survival, whereas 
in patients with a markedly impaired performance status 
(<  80%) a RIC conditioning was associated with better 
outcome as compared to MAC. Regarding donor selection, 
MSD transplant resulted in lower rates of aGVHD and 
NRM in comparison to other donor sources; of note, a CB 
or haplo transplant were associated with a low incidence 
of severe cGVHD and survival rates which were similar 
to those observed following MUD and superior to those 
following MMUD transplant.
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